select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Thromboembolism-Pipeline Review, H2 2015

Thromboembolism-Pipeline Review, H2 2015


  • Products Id :- GMDHC6873IDB
  • |
  • Pages: 100
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Thromboembolism-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Thromboembolism-Pipeline Review, H2 2015', provides an overview of the Thromboembolism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Thromboembolism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Thromboembolism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Thromboembolism Overview 9

Therapeutics Development 10

Pipeline Products for Thromboembolism-Overview 10

Pipeline Products for Thromboembolism-Comparative Analysis 11

Thromboembolism-Therapeutics under Development by Companies 12

Thromboembolism-Therapeutics under Investigation by Universities/Institutes 14

Thromboembolism-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Thromboembolism-Products under Development by Companies 18

Thromboembolism-Products under Investigation by Universities/Institutes 19

Thromboembolism-Companies Involved in Therapeutics Development 20

Bayer AG 20

Cereno Scientific AB 21

China Biologic Products, Inc. 22

Daiichi Sankyo Company, Limited 23

Gamma Therapeutics, Inc. 24

GlycoMimetics, Inc. 25

Green Cross Corporation 26

Isis Pharmaceuticals, Inc. 27

Portola Pharmaceuticals, Inc. 28

Sanofi 29

The International Biotechnology Center (IBC) Generium 30

Tobira Therapeutics, Inc. 31

Thromboembolism-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

alteplase biosimilar-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

antithrombin III (human)-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

betrixaban-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

C-3-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

edoxaban tosylate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Gammarin-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

GCC-2107-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GMI-1271-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ISIS-FXIRx-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Lysimab-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Protein for Thromboembolism-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

REG-2-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

rivaroxaban-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

semuloparin-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules to Inhibit HDAC for Thromboembolism-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

TAP-ANV-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

YG-001-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Thromboembolism-Recent Pipeline Updates 67

Thromboembolism-Dormant Projects 88

Thromboembolism-Discontinued Products 89

Thromboembolism-Product Development Milestones 90

Featured News & Press Releases 90

Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots 90

Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer 91

Jun 03, 2015: NICE guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 91

Apr 27, 2015: Daiichi Sankyo's Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe 92

Apr 15, 2015: Daiichi Sankyo's Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 93

Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 95

Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 96

Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 97

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 97

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

Number of Products under Development for Thromboembolism, H2 2015 10

Number of Products under Development for Thromboembolism-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Investigation by Universities/Institutes, H2 2015 19

Thromboembolism-Pipeline by Bayer AG, H2 2015 20

Thromboembolism-Pipeline by Cereno Scientific AB, H2 2015 21

Thromboembolism-Pipeline by China Biologic Products, Inc., H2 2015 22

Thromboembolism-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 23

Thromboembolism-Pipeline by Gamma Therapeutics, Inc., H2 2015 24

Thromboembolism-Pipeline by GlycoMimetics, Inc., H2 2015 25

Thromboembolism-Pipeline by Green Cross Corporation, H2 2015 26

Thromboembolism-Pipeline by Isis Pharmaceuticals, Inc., H2 2015 27

Thromboembolism-Pipeline by Portola Pharmaceuticals, Inc., H2 2015 28

Thromboembolism-Pipeline by Sanofi, H2 2015 29

Thromboembolism-Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 30

Thromboembolism-Pipeline by Tobira Therapeutics, Inc., H2 2015 31

Assessment by Monotherapy Products, H2 2015 32

Number of Products by Stage and Target, H2 2015 34

Number of Products by Stage and Mechanism of Action, H2 2015 36

Number of Products by Stage and Route of Administration, H2 2015 38

Number of Products by Stage and Molecule Type, H2 2015 40

Thromboembolism Therapeutics-Recent Pipeline Updates, H2 2015 67

Thromboembolism-Dormant Projects, H2 2015 88

Thromboembolism-Discontinued Products, H2 2015 89

List of Figures

Number of Products under Development for Thromboembolism, H2 2015 10

Number of Products under Development for Thromboembolism-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 32

Number of Products by Top 10 Targets, H2 2015 33

Number of Products by Stage and Top 10 Targets, H2 2015 33

Number of Products by Top 10 Mechanism of Actions, H2 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 35

Number of Products by Top 10 Routes of Administration, H2 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 37

Number of Products by Top 10 Molecule Types, H2 2015 39

Number of Products by Stage and Top 10 Molecule Types, H2 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Cereno Scientific AB

China Biologic Products, Inc.

Daiichi Sankyo Company, Limited

Gamma Therapeutics, Inc.

GlycoMimetics, Inc.

Green Cross Corporation

Isis Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Sanofi

The International Biotechnology Center (IBC) Generium

Tobira Therapeutics, Inc.

Thromboembolism Therapeutic Products under Development, Key Players in Thromboembolism Therapeutics, Thromboembolism Pipeline Overview, Thromboembolism Pipeline, Thromboembolism Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com